-
Prostaglandin E2 in Inflammation Assays
2026-09-10
Build more interpretable inflammation experiments with Prostaglandin E2 by combining receptor-aware dosing, solvent controls, and time-resolved readouts. The workflow also shows how PGE2 can complement hydrogel-based intervertebral disc degeneration models without confusing assay extension with evidence of therapeutic efficacy.
-
SAF312 TRPV1 Antagonism in Ocular Surface Pain
2026-09-10
Mogi and colleagues developed a translational preclinical profile for SAF312 (libvatrep), a potent, selective, noncompetitive antagonist of human TRPV1 designed for topical treatment of ocular surface pain. The study connected receptor pharmacology with ocular distribution, tolerability, and post-PRK wound-healing data, supporting further clinical evaluation while leaving efficacy in patients to be established.
-
Zolmitriptan: From Receptor Probe to Assay Design
2026-09-09
Zolmitriptan is a selective 5-HT1B receptor agonist used to dissect migraine and cluster headache biology. This guide goes beyond routine compound handling by showing how orthogonal assay design and insights from lysosomal antiviral research can improve serotonin receptor pharmacology without overextending the evidence.
-
Prostaglandin E2: Receptor Biology to Assays
2026-09-09
Explore how Prostaglandin E2 and its EP-receptor profile can be translated into better inflammation research assays. This article connects receptor pharmacology with the compartment-specific lessons of ulcerative-colitis drug delivery.
-
CDC42, NTCP Trafficking, and HBV Entry
2026-09-08
The reference study identifies CDC42 as a regulator of hepatitis B virus entry through two linked processes: Rab11-dependent delivery of NTCP to the plasma membrane and CDC42-dependent macropinocytosis. Its findings separate this pathway from clathrin-mediated endocytosis and provide a mechanistic framework for studying how host membrane trafficking controls HBV susceptibility.
-
SLC25A1, H3K27ac, and Cisplatin Resistance in HNSCC
2026-09-08
A 2026 npj Precision Oncology study links SLC25A1 upregulation to cisplatin resistance in head and neck squamous cell carcinoma through citrate-dependent acetyl-CoA production, H3K27ac-mediated transcription, and cellular senescence. The findings position SLC25A1 as a candidate biomarker and therapeutic target while highlighting the need for carefully controlled senescence and lysosomal β-galactosidase assays.
-
Neuromedin S (rat): Practical GPCR Assay Guide
2026-09-07
This guide provides practical handling, reconstitution, assay setup, and quality-control guidance for Neuromedin S (rat), SKU B5466, when no directly matched paper evidence is available. It supports controlled neuromedin U receptor and GPCR/G protein signaling research, but not diagnostic, therapeutic, or medical use.
-
Pifithrin-α: Mapping p53 in Ferroptosis
2026-09-07
A translational perspective on Pifithrin-α as a research-grade p53 inhibitor for separating apoptosis, ferroptosis, DNA-damage responses, and radioprotection mechanisms.
-
Benzyl-activated Streptavidin Magnetic Beads
2026-09-05
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide magnet-assisted capture of biotinylated proteins, nucleic acids, peptides, antibodies, and other targets from complex samples. They are suitable for affinity purification, immunoprecipitation, interaction assays, and screening, but preservative compatibility, elution conditions, and performance with non-biotinylated or highly hydrophobic samples require validation.
-
Zolmitriptan Workflow for 5-HT1B Research
2026-09-04
Build reproducible serotonin receptor assays with Zolmitriptan, a research compound suited to migraine and cluster headache models. This guide combines solvent control, time-resolved pharmacology, subtype validation, and lysosome-study-inspired experimental design without overstating cross-domain evidence.
-
Small Molecules Improve Pancreatic Ductal Organoids
2026-09-04
Liao and colleagues developed a small-molecule-based culture strategy for generating pancreatic ductal organoids with improved initiation efficiency, ductal-cell enrichment, and long-term expansion. The model retains heterogeneous ductal and acinar populations, making it useful for studying exocrine biology, cellular plasticity, pancreatic disease, and future drug-screening workflows.
-
Mubritinib (TAK 165): Reading Complex I Assays
2026-09-03
Mubritinib (TAK 165) is best interpreted through mitochondrial redox biology rather than a HER2-only framework. This article connects complex I inhibition with NAD+/NADH homeostasis to improve assay design in AML, PEL, and related cancer biology studies.
-
BET Inhibition in HPV-16 HNSCC: Study Insights
2026-09-03
This preprint examines how BET protein inhibition affects viral and cellular transcription in HPV-16-associated head and neck squamous cell carcinoma. Its central contribution is showing that responses are heterogeneous across models, while convergent effects on BRD4, c-Myc, E2F, CDKN1A, and cell-cycle control provide a framework for interpreting BET-targeted experiments.
-
Podophyllotoxin Beyond the Product Page
2026-09-02
A mechanism-first guide to using Podophyllotoxin as a microtubule benchmark in cancer biology, while interpreting autophagy and hepatocellular carcinoma findings from the distinct natural product JXE-23.
-
Flubendazole: Autophagy Research Guide
2026-09-02
Flubendazole is a benzimidazole-derived autophagy activator supplied for research use. This guide distinguishes its documented product properties from breast-cancer pathway evidence involving tumor-associated macrophage extracellular vesicles, miR-660, KLHL21, and NF-κB signaling.